ACET

Adicet Bio, Inc.

Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001720580 Biotech & Drug Discovery

$3.99 −0.29 (−6.78%)

Oct 23 4:00 PM ET · prev $4.28

Market cap

$40.1M

Nano cap

Consensus

Buy

92% Buy or better · 12 analysts

Median target

🔒 Subscribers only

1 year

−72.0%

from $14.24 · Oct 24

30 days

−51.8%

from $8.27

52-week range

$3.99–14.43

at the low

Avg volume 20D

327.6K

Sep 28 spike 2.15M

Short interest

485.5K

≈5.2% of shares · +78.5%

Days to cover

1.1

at average volume

Insider net

+$929.1K

1 buyer · 1 seller · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read BULLISH 3 reports · 90 days

Balance 0 bearish · 1 bullish · 2 neutral oldest → newest, height = score

Avg score

·High conf. 2/3 ·Next Earnings date, Nov 11, 2026

Strongest BULLISH Adicet Bio reported positive Phase 1 safety and efficacy data for prula-cel (formerly ADI-001), an…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

B Feb 18 to Feb 20 3 days of insider buys: $1.6M by 1 insider, avg $7.17
E Apr 2 Trial readout: T-60d Trial Readout: ADI-270 (Phase 2)
S Apr 7 to Apr 8 2 days of insider sells: $674.8K by 1 insider, avg $6.45
X Aug 14 Short interest falls 33.9% to 262.4K
R Sep 28 Adicet Bio reported positive Phase 1 safety and efficacy data for pr…
E Sep 28 Trading halt: Halt Resumed: ACET — trading resumed after LUDP (Volatilit…
E Sep 28 Trading halt: Trading Halt: ACET — LUDP (Volatility Trading Pause)
X Sep 30 Short interest jumps 78.5% to 485.5K

Signal stack

Where each data set points today.

InsidersBULLISH

1 insider bought $1.6M at an average $7.17. 1 insider sold $674.8K. Price is 44% below their cost.
InstitutionsBULLISH

Q2 2026: 6 added (0 new), 1 trimmed or exited.
AnalystsBULLISH

11 of 12 rate it Buy or better.
Short sellersBUILDING

Short interest +78.5% to 485.5K shares. 1.1 days to cover, ≈5.2% of shares.
TrendDOWNTREND

48% below its 50-day average. New closing low $3.99 on Oct 23.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
Trexquant Investment LP	ADD	78,002	$673.9K
JANE STREET GROUP, LLC	ADD	70,561	$609.6K
BlackRock, Inc.	ADD	62,126	$536.8K
DIMENSIONAL FUND ADVISORS LP	DOUBLED	31,603	$273.0K
SIMPLEX TRADING, LLC	DOUBLED	4,814	$41.6K
MORGAN STANLEY	TRIM	2,291	$19.8K
JPMORGAN CHASE & CO	DOUBLED	196	$1.7K
Woodline Partners LP	TRIM	313,124	$2.1M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts

Buy 92% rate it Buy or better

Strong Buy5Buy6Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access

Recent actions

Date	Firm	Action	Rating
Sep 29, 2026	Wedbush MAINTAIN	MAINTAIN	Outperform
Sep 28, 2026	HC Wainwright & Co. MAINTAIN	MAINTAIN	Buy
Sep 18, 2026	HC Wainwright & Co. REITERATE	REITERATE	Buy
Aug 6, 2026	Guggenheim MAINTAIN	MAINTAIN	Buy

Insider ledger

Form 4

$1.6M

bought · 1 insider

$674.8K

sold · 1 insider

−44.4%

vs their $7.17 cost

Date	Insider	Type	Value
Aug 5, 2026	Klickstein Lloyd Chief Medical Officer	AWARD	18,300 sh
Jun 21, 2026	Peng Katie Director	AWARD	4,200 sh
Jun 21, 2026	Sinclair Andrew Director	AWARD	4,200 sh
Jun 21, 2026	Grissinger Michael Director	AWARD	4,200 sh
Jun 21, 2026	Klickstein Lloyd Director	AWARD	4,200 sh
Jun 21, 2026	Chodakewitz Jeffrey Director	AWARD	4,200 sh
Jun 21, 2026	DUBIN STEVE Director	AWARD	4,200 sh
Jun 19, 2026	Aftab Blake Chief Scientific Officer	AWARD	55,000 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data — subscribers only

Period	EPS est.	Range	30D rev.	Revenue
Current Q	🔒 Fresh data — subscribers only
Next Q	🔒 Fresh data — subscribers only
Current FY	🔒 Fresh data — subscribers only
Next FY	🔒 Fresh data — subscribers only